Corbus Pharmaceuticals Holdings, Inc. - CRBP Enterprise Value-to-Sales Ratio

Official company branding of corbuspharma.com (CRBP)

The monetization of inflammatory process research creates a foundation for long-term partnerships with industry behemoths. The Enterprise Value to Sales ratio in the daily price action on the GURU.Markets chart helps identify overheating phases, where 0.00 represents the current metric value. The resilience of Corbus Pharmaceuticals (CRBP) is guaranteed by the non-cyclical nature of oncology development and a strict materials logistics protocol that completely eliminates transportation risks.

Corbus Pharmaceuticals, Inc. (CRBP): Company Value to Revenue from 11/23/2025 to 11/20/2026

Corbus Pharma - analytical breakdowns and key metrics (CRBP)

- cash balance and cash flow data:
Fundamental company valuation:CRBP, corbuspharma.com
Manufactured products of Corbus Pharmaceuticals Holdings, Inc.

This indicator determines the total business value relative to its annual revenue, excluding the impact of leverage. Investors utilize the EV/Revenue ratio to identify an asset's fair price regardless of its capital structure. An increase in this metric signals that the asset is overbought, while a decrease suggests potential undervaluation. For Corbus Pharmaceuticals (CRBP), this metric reflects market expectations regarding the commercialization of the selective drug CRB-701. High values here are justified by the uniqueness of ADC technologies in oncology.